2 Years of Treatment, 7 Years of Benefits: Abemaciclib Delivers New Overall Survival Data in Breast Cancer Patients

In this short video, Dr Nitesh Rohtagi, Principal Director, Department of Medical Oncology, Fortis Cancer Institute, Delhi and Gurugram, discusses key findings from ESMO 2025, highlighting that 2-year Abemaciclib therapy shows increasing benefit at seven years for patients with early breast cancer.^1,2

With a 16.5% reduction in the risk of death, it is a clear confirmation that Abemaciclib in early breast cancer given for 2 years has an overall survival advantage. ^1,2,3,4,5 It is also seen that deaths due to breast cancer are reduced from 11% to 8.3%. He also emphasized that there's a ~30% reduction in the number of patients living with metastatic disease than the control arm. It seems that this number will continue to become more apparent.¹

Abemaciclib, only CDK4 inhibitor, demonstrated a sustained an Invasive disease-free survival (IDFS) benefit at 7 years with just 2 years of therapy. It also delivers a long lasting protection by reducing the risk of recurrence of incurable metastatic disease. ^1,2

This is the longest follow-up ever reported with the CDK4/6 inhibitor in early breast cancer. Specifically, for the highest population which in India unfortunately is high, this two year’s treatment showing seven years’ benefit is meaningful and impactful. ^1,3,5,6

Tolerability has always been a point of discussion, but Abemaciclib demonstrated a reversible and manageable safety profile, with 81.5% of patients in the monarchE trial remaining on treatment. Most adverse events were predictable, tolerable, and low grade. The most common adverse effect was diarrhea, with a median time to onset of approximately 8 days and an average duration of 5 to 6 days. Notably, 94.7% of patients in monarchE continued treatment despite experiencing diarrhea, highlighting that with appropriate counseling and close support, patients can successfully manage toxicity.^6,7,8

When dose reductions are necessary to help patients manage side effects, Abemaciclib remains effective, and efficacy is preserved.⁶

Reference: 1 Johnston S, Martin M, O'Shaughnessy J, et al. Ann Oncol. 2025. DOI: 10.1016/j.annonc.2025.10.005 ESMO Presentation. 2025. 2. Ramiven India API Version Control No .: PA008SPIN05. 3. Hortobagyi GN, et al. Ann Oncol. 2025;36(2):149-57. 4. Ribociclib. Summary of Product Characteristics. April 2025. 5. Rastogi P, et al. J Clin Oncol. 2024;42(9):987-93. 5. Ramiven India API Version Control No .: PA008SPIN05. 6. Goetz MP, et al. NPJ Breast Cancer. 2024;10(1):34 (+Suppl. Appendix) 7. Johnston SRD, et al. Lancet Oncol. 2023;24(1):77-90. 8. Rugo HS, et al. Ann Oncol. 2022;33(6):616-27.

PP-AL-IN-1852 | 17/12/2025

Eli Lilly and Company (India) Private Limited

For further Information about Lilly and Lilly products please contact us at the below address: Plot 92, Sector 32 Gurgaon, Haryana, 122001, India Ph.: +91-124-4753000/01 | www.lilly.com/in

For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com | For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com.

This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner. This material is being provided to healthcare professionals only for their guidance and use. Nothing on this website/microsite/material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.

Ramiven India API

Lilly India Privacy Policy

© 2025 Eli Lilly and Company